p53 gene mutations in surgical margins and primary tumor tissues of patients with squamous cell carcinoma of the head and neck

Tumori

Volumn 93, Issue 2, 2007, Pages 182-188

  Tunca, Berrin ^a   Erisen, Levent ^a   Coskun, Hakan ^a   Cecener, Gulsah ^a   Ozuysal, Sema ^a   Egeli, Unal ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

p53 gene; Single strand conformational polymorphism analysis; Squamous cell carcinoma of head and neck; Surgical margins; Tumor sample

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HEAD; HEAD AND NECK CANCER; HUMAN; MALE; NECK; RECURRENT DISEASE; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TUMOR;

EID: 34249902802     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300212     Document Type: Article

References (48)

1. Boring CC, Squire TS, Tong T: Cancer statistics. CA Cancer J Clin, 42: 18-381, 1992.
2. Tuyns AJ, Esteve J, Raymond L, Berrino F, Benhamou E, Blanchet F, Boffetta P, Crosignani P, del Moral A, Lehmann W, Merletti F, Pequignot G, Rreou E, Sancho-Garnier H, Terracini B, Zubiri A, Zubiri L: Cancer of larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer, 41: 483-491, 1988.
3. Egeli U, Ozkan L, Tunca B, Kahraman S, Cecener G, Ergul E, Engin K: The relationship between genetic susceptibility to head and neck cancer with the expression of common fragile sites. Head Neck, 22: 591-598, 2000.
4. Califano J, Van der Riet P, Westra W, Nawroz H, Clayman G, Piantodosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res, 56: 2488-2492, 1996.
5. Blons H, Laurent-Puig P: TP53 and head and neck neoplasms. Hum Mutat, 21: 252-257, 2003.
6. Saunders ME, MacKenzie R, Shipman R, Fransen E, Gilbert R, Jordan RC: Patterns of p53 gene mutations in head and neck cancer: Full-length gene sequencing and results of primary radiotherapy. Clin Cancer Res, 5: 2455-2463, 1999.
7. Alsner J, Sorensen SB, Overgaard J: TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol, 59: 179-185, 2001.
8. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA, Sidransky D: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med, 332: 712-717, 1995.
9. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol, 18: 1465-1473, 2000.
10. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D: Evidence for a casual association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst, 92: 709-720, 2000.
11. Ko Y, Abel J, Harth V, Brode P, Antony C, Donat S, Fischer HP, Ortiz-Pallardo ME, Thier R, Sachinidis A, Vetter H, Bolt HM, Herberhold C, Bruning T: Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res, 61: 4398-4404, 2001.
12. Temam S, Flahault A, Perie S, Monceaux G, Coulet F, Callard P, Bernaudin JF, St Guily JL, Fouret P: p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol, 18: 385-394, 2000.
13. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM, Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res, 53: 4477-4480, 1993.
14. Houten VMM, Tabor MP, Brekel MWM, Kummer A, Denkers F, Dijkstra J, Leemans R, Wall I, Snow GB, Brakenhoff RH: Mutated p53 as a molecular marker for the diagnosis of the head and neck cancer. Pathology, 198: 476-486, 2002.
15. Leemans CR, Tiwari R, Nauta JJ, Van der Waal I, Snow GB: Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer, 73: 187-190, 1994.
16. Hermanek P, Hutter RV, Sobin LH, Wittekind C: Classification of isolated tumor cells and micrometastasis. Cancer, 86: 2668-2673, 1999.
17. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, Caporaso NE, Fraumeni JF Jr, Rice JM: Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res, 55: 2665-2672, 1995.
18. Sanger F, Nicklen S, Caulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA, 74: 463-67, 1977.
19. Toyooka S, Tsuda T, Gazdar AF: The TP53 gene, tobacco exposure and lung cancer. Hum Mutat, 21: 229-239, 2003.
20. Vos M, Adams CH, Victor TC, van Helden PD: Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genet Cytogenet, 140: 23-30, 2003.
21. Montesano R, Hollstein M, Hainaut P: Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer (Pred Oncol), 69: 225-235, 1996.
22. Wagara T, Shibagaki I, Imamura M, Shimada Y, Toguchida J, Yandell DW, Ikenaga M, Tobe T, Ishizaki K: Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res, 53: 846-850, 1993.
23. Beroud C, Soussi T: The UMD-p53 Database: New mutations and analysis tools. Hum Mutat, 21: 176-181, 2003.
24. Soussi T, Dehouche K, Beroud C: P53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat, 15: 105-113, 2000.
25. Iacopetta B: TP53 mutation in colorectal cancer. Hum Mutat, 21: 271-276, 2003.
26. Hainaut P, Oliver M, Pfeifer GP: TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. Mutagenesis, 16: 551-553, 2001.
27. Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, Pfeifer GP: Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst, 92: 803-811, 2000.
28. Bergh J, Norberk T, Sjogren S, Lindgren A, Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med, 1: 1029-1034, 1995.
29. Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR: Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clinical Cancer Res, 6: 443-451, 2000.
30. Jin YT, Kayser S, Kemp BL, Ordonez NG, Tucker SL, Clayman GL, Goepfert H, Luna MA, Batsakis JG, El-Naggar AK: The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma. Cancer, 82: 2159-2165, 1998.
31. Shin DM, Mao L, Papadimitrakopoulou VM, Clayman G, El-Naggar A, Shin HJ, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK: Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst, 92: 69-73, 2000.
32. Georgiou A, Gomatos IP, Ferekidis E, Syrigos K, Bistola V, Giotakis J, Adamopoulos G, Androulakis G: Prognostic significance of p53, bax and bcl-2 gene expression in patients with laryngeal carcinoma. Eur J Surg Oncol, 27: 574-580, 2001.
33. Gonzalez-Moles MA, Galindo P, Gutierrez-Fernandez J, Sanchez-Fernandez E, Rodriguez-Archilla A, Ruiz-Avila I, Brovo M: P53 protein expression in oral squamous cell carcinoma. Survival analysis. Anticancer Res, 21: 2889-2894, 2001.
34. Hirvikoski P, Kumpulainen E, Virtaniemi J, Johansson R, Haapasalo H, Marin S, Halonen P, Helin H, Raitiola H, Pukander J, Kellokumpu-Lehtinen P, Kosma VM: P53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol, 15: 3111-3120, 1997.
35. Jeannon JP, Soames J, Lunec J, Awwad S, Ashton V, Wilson JA: Expression of cylin-dependent kinase inhibitor p21 (WAF1) and p53 tumour suppressor gene in laryngeal cancer. Clin Otolaryngol, 25: 23-27, 2000.
36. Kokoska MS, Piccirillo JF, el-Mofty SK, Emami B, Haughey BH, Schoinick SB: Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy. Cancer, 78: 1693-1700, 1996.
37. Sittel C, Eckel HE, Damm M, von Pritzbuer E, Kvasnicka HM: Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma. Laryngoscope, 110: 1012-1017, 2000.
38. Mineta H, Borg A, Dictor M, Wahlberg P, Akervall J, Wennerberg J: p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer, 78: 1084-1090, 1998.
39. Bandoh N, Hayashi T, Kishibe K, Takahara M, Imada M, Nonaka S, Harabuchi Y: Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma. Cancer, 94: 1968-1980, 2002.
40. Bradford CR, Zhu S, Poore J, Fisher SG, Beals TF, Thoraval D, Hanash SM, Carey TE, Wolf GT: P53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of veterans affair laryngeal cancer cooperative study group. Arch Otolaryngol Head Neck Surg, 123: 605-609, 1997.
41. Chow V, Yuen AP, Lam KY, Ho WK, Wei WI: Prognostic significance of serum p53 protein and p53 antibady in patients with surgical treatment for head and neck squamous cell carcinoma. Head Neck, 23: 286-291, 2001.
42. Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschini L, Porfirio B: Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer, 84: 573-579, 1999.
43. Partridge M, Li SR, Pateromichelakis S, Francis R, Phillips E, Huang XH, Tesfa-Selase F, Langdon JD: Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clinical Cancer Res, 6: 2718-2725, 2000.
44. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med, 332: 429-435, 1995.
45. Tabor MP, Brakenhoff RH, van Houten VMM, Kummer A, Snel MHJ, Snijders PJF, Snow GB, Leemans CR, Braakhuis BJM: Persistence of genetically altered fields in head and neck cancer patients: Biological and clinical implications. Clinical Cancer Res, 7: 1523-1532, 2001.
46. Mao L, Lee JS, Fan YH, Rao JY, Batsakis JG, Lippman S, HiHelman W, Hong WK: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Med, 2: 682-685, 1996.
47. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Berean K, Epstein JB, Priddy R, Le ND, Zhang L: Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res, 6: 357-362, 2000.
48. Patridge M, Pateromichelakis S, Phillips E, Emilion GG, A'Hern RP, Langdon JD: A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma with in a field of cancerization. Cancer Res, 60: 3893-3898, 2000.